Ernexa Therapeutics Inc.

Contributing Author

Recent Articles by Ernexa Therapeutics Inc.

Jul-24	Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies ERNA GlobeNewswire
Jul-15	Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry ERNA +11.06% GlobeNewswire
Jul-14	Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 ERNA +9.39% GlobeNewswire
Jun-25	Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients ERNA +17.46% GlobeNewswire
Jun-17	Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study ERNA GlobeNewswire
Jun-09	Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer ERNA -7.98% GlobeNewswire
May-27	Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development ERNA GlobeNewswire
May-20	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity ERNA GlobeNewswire
May-11	Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 ERNA GlobeNewswire
May-06	Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models ERNA +51.38% GlobeNewswire
Apr-30	Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split ERNA -21.24% GlobeNewswire
Mar-31	Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 ERNA +5.29% GlobeNewswire
Feb-20	Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series ERNA -17.25% GlobeNewswire
Feb-06	Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering ERNA -44.66% GlobeNewswire
Feb-03	Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA ERNA -25.80% GlobeNewswire
Jan-27	Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program ERNA GlobeNewswire
Jan-06	Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer ERNA GlobeNewswire
Dec-08	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer ERNA GlobeNewswire
Dec-03	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting ERNA GlobeNewswire
Dec-02	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG ERNA GlobeNewswire
Nov-11	Ernexa Therapeutics to Present at Oxford Global's Cell 2025 ERNA -5.39% GlobeNewswire
Nov-10	Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials ERNA GlobeNewswire
Nov-06	Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform ERNA GlobeNewswire
Oct-01	Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa ERNA GlobeNewswire
Sep-29	Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit ERNA GlobeNewswire
Sep-17	Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research ERNA -5.22% GlobeNewswire
Sep-10	Ernexa Therapeutics Provides Update on Operational Excellence and Performance ERNA GlobeNewswire
Sep-03	Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference ERNA GlobeNewswire
Jul-09	Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements ERNA GlobeNewswire
Jun-25	Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development ERNA -5.05% GlobeNewswire
Jun-24	Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement ERNA -17.50% GlobeNewswire
Jun-10	Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split ERNA -17.99% GlobeNewswire
May-28	Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 ERNA GlobeNewswire
May-14	Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations ERNA +13.11% GlobeNewswire

Ernexa Therapeutics Inc.

Recent Articles by Ernexa Therapeutics Inc.

Upgrade your Finviz experience